The Federal Trade Commission announced Friday it has cleared the latest pharmaceutical merger proposal as a string of deals in the industry sweeps across the globe.
Forest Laborites has been cleared to acquire Furiex Pharmaceuticals, a deal made for $1.46 billion, according to reports. Forest first announced in late April that it plans to acquire the company for its gastrointestinal treatment portfolio.
The merger is one of many in the works for the pharmaceutical market, though not all are sure to consummate. Recently, Pfizer failed to acquire AstraZeneca despite several bids that ultimately reached a $119 billion offer. Additionally, Valeant is currently looking to acquire the maker of Botox, Allergan, and has also recently increased its offer.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Probes Lindab’s Acquisition of HAS-Vent Amid Fears of Market Monopoly
Apr 28, 2024 by
CPI
Shein Faces EU Regulations Over User Data
Apr 28, 2024 by
CPI
Google Fights Back Against US Antitrust Lawsuit
Apr 28, 2024 by
CPI
US Homeland Security Establishes Blue-Ribbon Board with Tech CEOs to Advise on AI
Apr 28, 2024 by
CPI
FTC Accuses Amazon Executives of Using Disappearing Messaging Apps to Conceal Evidence
Apr 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI